STAT+: Pharmalot: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more

The FDA is increasingly reducing the number of public advisory committee meetings, which has raised concerns among stakeholders, including drugmakers, patients, and doctors, who seek greater transparency in the agency's decision-making processes. This shift comes at a time when the public and various stakeholders are advocating for more opportunities to express their views on drug approvals and regulatory practices (Stat News: STAT+: As controversial decisions mount, FDA shuns public advisory meetings). In a notable instance of this trend, the FDA recently rejected an experimental therapy intended to treat a rare blood cancer, despite internal reviewers recommending it for approval. This unexpected decision has led to confusion and frustration among drugmakers and advocates for rare diseases, who believed they had received the agency's support for the therapy's clearance. The rejection has intensified concerns about the FDA's evaluation criteria and its communication with stakeholders in the pharmaceutical industry (Stat News: STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA). Families affected by rare diseases have expressed their discontent over the FDA's inconsistent signals regarding drug approvals. Many feel a sense of whiplash due to the shifting and contradictory decisions made by the agency, which can significantly impact their hopes for effective treatments. The implications of the recent rejection extend beyond the immediate therapy, affecting the overall landscape for drug approvals in the context of rare diseases (Stat News: STAT+: Rare disease advocates fume over FDA’s mixed signals). This situation is part of a broader narrative involving various pharmaceutical developments, including a weight loss pill from Lilly. However, the primary focus remains on the puzzling rejection of the rare disease therapy, which has raised questions about the FDA's evaluation criteria and its communication with stakeholders in the pharmaceutical industry (Stat News: STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more).